Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesAmortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Innoviva (INVA) Shares Outstanding (Diluted Average) (2009 - 2012)

Innoviva posted quarterly Shares Outstanding (Diluted Average) of $98.4 million for Q3 2012, up 19.26% year-on-year from $82.5 million in Q4 2011, and up 3.51% on a QoQ basis from $95.0 million in Q2 2012.

Innoviva (INVA) has 4 years of Shares Outstanding (Diluted Average) data on file, last reported at $98.4 million in Q3 2012.

  • For the quarter ending Q3 2012, Shares Outstanding (Diluted Average) rose 19.26% year-over-year to $98.4 million; the trailing twelve-month figure through Sep 2012 stood at $98.4 million (up 19.26% YoY), and the FY2011 full-year result was $82.1 million, up 13.85% from the prior year.
  • Shares Outstanding (Diluted Average) for Q3 2012 stood at $98.4 million, up from $95.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $98.4 million in Q3 2012 and bottomed at $63.0 million in Q4 2009.
  • The 4-year median for Shares Outstanding (Diluted Average) is $81.8 million (2011), against an average of $79.9 million.
  • The widest annual swing landed in 2011, when Shares Outstanding (Diluted Average) advanced 11.64%; it then grew 19.26% in 2012.
  • A 4-year view of Shares Outstanding (Diluted Average) shows it stood at $63.0 million in 2009, then gained by 14.35% to $72.1 million in 2010, then rose by 13.85% to $82.1 million in 2011, then grew by 19.9% to $98.4 million in 2012.
  • The last three Shares Outstanding (Diluted Average) figures came in at $98.4 million (Q3 2012), $95.0 million (Q2 2012), and $82.1 million (Q4 2011), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares (Diluted Avg.) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 3.06 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 810.00
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 118.76 Bn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 256.30 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 107.70 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 138.23 Mn
10 Innoviva 1.60 Bn 992.84 Mn 75.83 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2012 98.38 Mn
Jun 30, 2012 95.04 Mn
Dec 31, 2011 82.05 Mn
Sep 30, 2011 82.49 Mn
Jun 30, 2011 81.81 Mn
Dec 31, 2010 72.07 Mn
Sep 30, 2010 70.68 Mn
Jun 30, 2010 73.28 Mn
Dec 31, 2009 63.03 Mn